#HVO hVIVO PLC – Holding(s) in Company June 9, 2026 – Posted in: hVIVO (HVO), Uncategorized
Octopus Investments has increased its shareholding from 13.06% to 14.4% (97,312,186 shares) Link here to view the full announcement
Continue reading
Octopus Investments has increased its shareholding from 13.06% to 14.4% (97,312,186 shares) Link here to view the full announcement
Continue readingLondon, UK – 1 June 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces it has signed a consultancy contract with Decoy Therapeutics (“Decoy”) to support the development of its respiratory antiviral candidates. Decoy is developing a portfolio of Designable Multi-Antiviral (D-MAV) candidates, a new antiviral category designed to address multiple viruses by targeting shared viral mechanisms across multiple respiratory viruses using a single…
Continue readingLondon, UK – 13 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that all resolutions put to shareholders at the Company’s Annual General Meeting (‘AGM’) held earlier today were duly passed. The voting results of the AGM will be published on the Company website shortly: https://hvivo.com/company-documents/ For further information please contact: hVIVO plc +44 (0)20 7756 1300 Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial…
Continue readingStockbox podcast with Alan Green, Mark Fairbairn and Dan Flynn covers: Panther Metals #PALM hVIVO #HVO Cosmo Metals #CMO Trifast #TRI
Continue readingLondon, UK – 15 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces its audited results for the year ended 31 December 2025. Financial highlights · Revenue of £46.8 million (2024: £62.7 million) · Positive adjusted EBITDA of £1.4 million (2024: £16.4 million) · Adjusted EBITDA margin of 3.0% (2024: 26.2%) · Basic adjusted earnings per share of (0.41)p (2024: 1.69p) ·…
Continue readingLondon, UK – 14 April 2026 hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it has signed a Clinical Trial Agreement (“CTA”) to conduct a human challenge (HCT) trial on behalf of Traws Pharma (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases. The trial will test Traws’ prophylactic antiviral candidate, tivoxavir marboxil (“TXM”), using the hVIVO Influenza Human Challenge…
Continue readingLondon, UK – 7 April 2026, hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it will release its final results for the year ended 31 December 2025 on Wednesday 15 April 2026. Analyst briefing A briefing open to equity research analysts will take place on Wednesday 15 April 2026 at 11.00am BST. To register and for more details please contact hVIVO@icrhealthcare.com. Investor presentation Yamin ‘Mo’ Khan,…
Continue readingLondon, UK – 23 February 2026, hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the issue of 1,386,991 new Ordinary Shares of £0.001 each in the Company (“First Consideration Shares”) to three managers of Cryo-Store Limited (“Cryostore”). This issuance comprises the first tranche (50%) of the equity consideration payable pursuant to the acquisition of Cryostore announced on 27 February 2025 (the “Acquisition”). …
Continue readinghVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the appointment of Richard Cotton as Independent Non-Executive Director, effective today. Richard will also serve as Chair of the Audit Committee and as a member of the Remuneration and Nominations Committees. Richard brings extensive Board-level and financial expertise, including experience serving as Chair, Audit Chair and Senior Independent Director, as well as holding advisory…
Continue readinghVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on 15 December 2025, Yamin ‘Mo’ Khan, Chief Executive Officer and Stephen Pinkerton, Chief Financial Officer, purchased shares in the Company as detailed below: Director Number of ordinary shares purchased Purchase price Resultant holding Resultant holding as a % of the issued share capital Yamin ‘Mo’ Khan 3,310,405 6.04p 8,322,008 1.21% Stephen Pinkerton 520,000 5.5p 1,270,596*…
Continue reading
